248 related articles for article (PubMed ID: 1703226)
1. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
[TBL] [Abstract][Full Text] [Related]
2. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E
Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.
Tilly H; Mounier N; Lederlin P; Brière J; Dupriez B; Sebban C; Bosly A; Biron P; Nouvel C; Herbrecht R; Bordessoule D; Coiffier B
J Clin Oncol; 2000 Mar; 18(6):1309-15. PubMed ID: 10715302
[TBL] [Abstract][Full Text] [Related]
5. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.
Diviné M; Lepage E; Brière J; Pautier P; Dupriez B; Lederlin P; Mineur P; Tilly H; Blanc M; Audhuy B; Herbrecht R; Coiffier B; Reyes F
J Clin Oncol; 1996 Jan; 14(1):240-8. PubMed ID: 8558204
[TBL] [Abstract][Full Text] [Related]
6. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs.
Salles G; Herbrecht R; Tilly H; Berger F; Brousse N; Gisselbrecht C; Coiffier B
Am J Med; 1991 Jan; 90(1):77-84. PubMed ID: 1702581
[TBL] [Abstract][Full Text] [Related]
7. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.
Coiffier B; Gisselbrecht C; Herbrecht R; Tilly H; Bosly A; Brousse N
J Clin Oncol; 1989 Aug; 7(8):1018-26. PubMed ID: 2474057
[TBL] [Abstract][Full Text] [Related]
8. Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
Colombat P; Guilhot F; Bordesoule D; Renou P; Benz-Lemoine E; Fouillard L; Drouet M; Tanzer J; Lamagnere JP
Haematologica; 1991; 76(6):479-84. PubMed ID: 1726492
[TBL] [Abstract][Full Text] [Related]
9. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
Haioun C; Lepage E; Gisselbrecht C; Coiffier B; Bosly A; Tilly H; Morel P; Nouvel C; Herbrecht R; D'Agay MF
J Clin Oncol; 1994 Dec; 12(12):2543-51. PubMed ID: 7527453
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Lepage E; Gisselbrecht C; Haioun C; Sebban C; Tilly H; Bosly A; Morel P; Herbrecht R; Reyes F; Coiffier B
Ann Oncol; 1993 Sep; 4(8):651-6. PubMed ID: 7694634
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Haioun C; Lepage E; Gisselbrecht C; Salles G; Coiffier B; Brice P; Bosly A; Morel P; Nouvel C; Tilly H; Lederlin P; Sebban C; Brière J; Gaulard P; Reyes F
J Clin Oncol; 2000 Aug; 18(16):3025-30. PubMed ID: 10944137
[TBL] [Abstract][Full Text] [Related]
12. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.
Mounier N; Morel P; Haioun C; Coiffier B; Tilly H; Chatelain C; Lederlin P; Thyss A; Herbrecht R; Gisselbrecht C; Lepage E
Cancer; 1998 May; 82(10):1952-62. PubMed ID: 9587130
[TBL] [Abstract][Full Text] [Related]
13. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group.
Gisselbrecht C; Oksenhendler E; Tirelli U; Lepage E; Gabarre J; Farcet JP; Gastaldi R; Coiffier B; Thyss A; Raphael M
Am J Med; 1993 Aug; 95(2):188-96. PubMed ID: 7689296
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
16. Results of the cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) +/- bleomycin treatment and evaluation of prognostic factors in aggressive lymphomas in Turkey.
Dinçol D; Akbulut H; Içli F; Samur M; Karaoğuz H; Demirkazik A; Cay F
Oncology; 1997; 54(5):376-9. PubMed ID: 9260598
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors, late relapse and outcome of patients with aggressive malignant lymphoma: long term results of LNH-80 protocol].
Dumontet C; Bastion Y; Felman P; Ffrench M; Blanc M; Peaud PY; Bryon PA; Coiffier B
Bull Cancer; 1992; 79(10):979-89. PubMed ID: 1284041
[TBL] [Abstract][Full Text] [Related]
18. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).
Coiffier B; Brousse N; Peuchmaur M; Berger F; Gisselbrecht C; Bryon PA; Diebold J
Ann Oncol; 1990; 1(1):45-50. PubMed ID: 1706610
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen.
Bosly A; Coiffier B; Gisselbrecht C; Tilly H; Auzanneau G; Andrien F; Herbrecht R; Legros M; Devaux Y; Jaubert J
J Clin Oncol; 1992 Oct; 10(10):1615-23. PubMed ID: 1383435
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
